

**APF822Hu01 100µg**  
**Active Phosphatase And Tensin Homolog (PTEN)**  
**Organism Species: *Homo sapiens* (Human)**  
***Instruction manual***

FOR RESEARCH USE ONLY  
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

---

---

1st Edition (Apr, 2016)

## **[ PROPERTIES ]**

**Source:** Prokaryotic expression.

**Host:** *E. coli*

**Residues:** Thr2~Val403

**Tags:** N-terminal His-tag

**Purity:** >92%

**Endotoxin Level:** <1.0EU per 1µg (determined by the LAL method).

**Buffer Formulation:** 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl and 5% trehalose.

**Applications:** Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

**Predicted isoelectric point:** 5.9

**Predicted Molecular Mass:** 48.0kDa

**Accurate Molecular Mass:** 55kDa as determined by SDS-PAGE reducing conditions.

### **Phenomenon explanation:**

The possible reasons that the actual band size differs from the predicted are as follows:

1. Splice variants: Alternative splicing may create different sized proteins from the same gene.
2. Relative charge: The composition of amino acids may affects the charge of the protein.
3. Post-translational modification: Phosphorylation, glycosylation, methylation etc.
4. Post-translation cleavage: Many proteins are synthesized as pro-proteins, and then cleaved to give the active form.
5. Polymerization of the target protein: Dimerization, multimerization etc.

## [ USAGE ]

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

## [ STORAGE AND STABILITY ]

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.


## [ SEQUENCE ]

```
TAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI
DDVVRFLDSK HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL
IKPFCEDLDQ WLSEDDNHVA AIHCKAGKGR TGVMICAYLL HRGKFLKAQE
ALDFYGEVRT RDKKGV TIPS QRRYVYYYSY LLKNHLDYRP VALLFHKMMF
ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY FEFPQPLPVC
GDIKVEFFHK QNKMLKKDKM FHFVNTFFI PGPEETSEKV ENGLCDQEI
DSICSIERAD NDKEYLVLT TL TKNDLDKANK DKANRYFSPN FKVKLYFTKT
VEEPSNPEAS SSTSVPDVS DNEPDHYRYS DTTSDPENE PFDEDQHTQI
TKV
```

## [ ACTIVITY ]

Phosphatase and tensin homolog (PTEN) is a protein is widely expressed throughout the body. PTEN protein acts as a phosphatase to dephosphorylate phosphatidylinositol (3,4,5)-trisphosphate (PtdIns (3,4,5)P3 or PIP3). PTEN specifically catalyses the dephosphorylation of the 3' phosphate of the inositol ring in PIP3, resulting in the biphosphate product PIP2 (PtdIns (4,5) P2). PTEN also


has weak protein phosphatase activity, but this activity is also crucial for its role as a tumor suppressor. PTEN's protein phosphatase activity may be involved in the regulation of the cell cycle, preventing cells from growing and dividing too rapidly. Besides, Tumor Protein p53 (TP53) has been identified as an interactor of PTEN, thus a binding ELISA assay was conducted to detect the interaction of recombinant human PTEN and recombinant human TP53. Briefly, PTEN were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 $\mu$ L were then transferred to TP53-coated microtiter wells and incubated for 2h at 37 $^{\circ}$ C. Wells were washed with PBST and incubated for 1h with anti-PTEN pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37 $^{\circ}$ C. Finally, add 50 $\mu$ L stop solution to the wells and read at 450nm immediately. The binding activity of PTEN and TP53 was shown in Figure 1, and this effect was in a dose dependent manner.




**Figure 1. The binding activity of PTEN with TP53.**

## [ IDENTIFICATION ]

DGGLTCTCAGAGCTGATCGAGCAAGGCGMAGGCGTGTCTCAGCTGCTGCMHTRVQGHGHTTCTGHTGHTTDTGCGAGCTGKAGCGAGGCGGCHMTRGSGTSCGAGCTTGGTCAKGTGAAKGMTCAGGDDCHTCTTCTGAGGCHTRGCGGCGGCGGCGMHTTATTCGGTTCGHTTCTTCTG  
TATIKETVSRNKRRYQEDGFDLDTTYIYFNITANQFPAPERLEGVYRNMIDDVYRFLDSKHHNHVKIYNDCAERHYDTARFNCRVAQYFFE




**Figure 2. Gene Sequencing (extract)**



**Figure 3. SDS-PAGE**

**Sample: Active recombinant PTEN, Human**



**Figure 4. Western Blot****Sample: Recombinant PTEN, Human;****Antibody: Rabbit Anti-Human PTEN Ab (PAF822Hu01)****[ IMPORTANT NOTE ]**

The kit is designed for in vitro and research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.